Description(s):
EGFR (Epidermal Growth Factor Receptor) is a transmembrane tyrosine kinase receptor that plays a crucial role in cell growth, division, and death. Mutations in the EGFR gene can lead to abnormal activation of the receptor, contributing to the development and progression of certain cancers.
 
Signosis has developed EL-039, a Ba/F3 cell line expressing EGFR that includes the insertion of amino acid H (His) between the position H773 and V774, and a point mutation that changes a C (Cys) into an S (Ser) at point 797. The C797S mutation in particular is known to confer resistance to EGFR inhibitors such as osimertinib and poziotinib, while the H773_V774insH mutation is one of the five most common EGFR exon 20 insertions encoutered during clinical care.
 
This cell line was established by electroporation to transfect Ba/F3 cells a vector containing the mutated EGFR gene with GFP and hygromycin resistance. Clones with resistance to hygroymcin were subsequently screened for GFP expression, with protein expression of the mutant EGFR tested via western blot. The clone with the highest expression were selected and expanded to produce this stable cell line.